BB2121 anti-BCMA CAR T cell therapy in MM

BB2121 is a second-generation CAR T cell therapy targeting B cell maturation antigen (BCMA) to kill malignant myeloma (MM) cells. Initial data from the dose-escalation first-in-human study of BB2121 in 21 heavily pretreated patients with relapsed/refractory (R/R) MM (CRB-401) had shown promising efficacy and safety. Dr. Jesús Berdeja (Sarah Cannon research Institute, Nashville, USA) presented an update (5 month follow-up). At active doses, BB2121 induces durable responses, with a median PFS of 11.8 months. All  of 16 evaluable responding patients were MRD-negative. There was a dose-response relationship across the active dose range and a higher peak CAR T cell expansion in responders. The safety profile has been manageable at doses as high as 800x106 CAR T cells.

Visit the EHA Learning Center to view the abstract.